AUPH
Aurinia Pharmaceuticals Inc.
Biotechnology
Market Cap$2.12B
5Y Perf.+1.1%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
AUPH vs LGND vs RARE vs FOLD
Revenue, margins, valuation, and 5-year total return — side by side.
LGND
Ligand Pharmaceuticals Incorporated
Biotechnology
Market Cap$4.57B
5Y Perf.+128.7%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.46B
5Y Perf.-63.5%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.47B
5Y Perf.+15.9%
AUPH vs LGND vs RARE vs FOLD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AUPH | LGND | RARE | FOLD |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $2.12B | $4.57B | $2.46B | $4.47B |
| Revenue (TTM) | $283M | $251M | $673M | $599M |
| Net Income (TTM) | $287M | $49M | $-575M | $-14M |
| Gross Margin | 88.5% | 85.9% | 83.8% | 89.5% |
| Operating Margin | 37.1% | 7.0% | -79.6% | 5.5% |
| Forward P/E | 19.7x | 26.1x | — | 40.6x |
| Total Debt | $75M | $7M | $1.28B | $444M |
| Cash & Equiv. | $80M | $72M | $434M | $214M |
AUPH vs LGND vs RARE vs FOLD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AUPH
LGND
RARE
FOLD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Aurinia Pharmaceuti… (AUPH) | 100 | 101.1 | +1.1% |
| Ligand Pharmaceutic… (LGND) | 100 | 228.7 | +128.7% |
| Ultragenyx Pharmace… (RARE) | 100 | 36.5 | -63.5% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AUPH vs LGND vs RARE vs FOLD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AUPH and FOLD are tied at the top with 3 categories each — the right choice depends on your priorities. Amicus Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
AUPH
Aurinia Pharmaceuticals Inc.
The Long-Run Compounder
AUPH carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 487.5% 10Y total return vs FOLD's 121.9%
- Lower P/E (19.7x vs 40.6x)
- 101.5% margin vs RARE's -85.5%
- 38.2% ROA vs RARE's -43.1%, ROIC 16.6% vs -89.4%
Best for: long-term compounding
LGND
Ligand Pharmaceuticals Incorporated
The Income Pick
LGND is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.99
- Lower volatility, beta 0.99, Low D/E 0.9%, current ratio 8.93x
Best for: income & stability and sleep-well-at-night
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
FOLD
Amicus Therapeutics, Inc.
The Growth Play
FOLD is the #2 pick in this set and the best alternative if growth exposure and defensive is your priority.
- Rev growth 32.3%, EPS growth 64.7%, 3Y rev CAGR 20.0%
- Beta 0.63, current ratio 3.39x
- 32.3% revenue growth vs RARE's 20.1%
- Beta 0.63 vs RARE's 1.42
Best for: growth exposure and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FOLD | 32.3% revenue growth vs RARE's 20.1% |
| Value | AUPH | Lower P/E (19.7x vs 40.6x) |
| Quality / Margins | AUPH | 101.5% margin vs RARE's -85.5% |
| Stability / Safety | FOLD | Beta 0.63 vs RARE's 1.42 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +121.9% vs RARE's -35.7% |
| Efficiency (ROA) | AUPH | 38.2% ROA vs RARE's -43.1%, ROIC 16.6% vs -89.4% |
AUPH vs LGND vs RARE vs FOLD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
FY 2025
Segment breakdown not available.
AUPH vs LGND vs RARE vs FOLD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAUPHLAGGINGRARE
Who Leads Where
AUPH leads in 3 of 6 categories
LGND leads 1 • FOLD leads 1 • RARE leads 0
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
FOLDAmicus Therapeutics, …
1leads
LGNDLigand Pharmaceutical…
1leads
AUPHAurinia Pharmaceutica…
3leads
6 Total Categories
CATEGORYLEADERvs LGNDvs FOLDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AUPH4/6
Valuation MetricsMultiples, price ratios, and targets
AUPH4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AUPH5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LGND4/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AUPH leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $673M annually — 2.7x LGND's $251M. AUPH is the more profitable business, keeping 101.5% of every revenue dollar as net income compared to RARE's -85.5%. On growth, LGND holds the edge at +122.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AUPHAurinia Pharmaceu… | LGNDLigand Pharmaceut… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $283M | $251M | $673M | $599M |
| EBITDAEarnings before interest/tax | $105M | $52M | -$501M | $40M |
| Net IncomeAfter-tax profit | $287M | $49M | -$575M | -$14M |
| Free Cash FlowCash after capex | $135M | $31M | -$472M | $10M |
| Gross MarginGross profit ÷ Revenue | +88.5% | +85.9% | +83.8% | +89.5% |
| Operating MarginEBIT ÷ Revenue | +37.1% | +7.0% | -79.6% | +5.5% |
| Net MarginNet income ÷ Revenue | +101.5% | +19.3% | -85.5% | -2.3% |
| FCF MarginFCF ÷ Revenue | +47.8% | +12.2% | -70.2% | +1.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +28.8% | +122.8% | +25.5% | +19.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +152.0% | +15.6% | +7.2% | +3.8% |
AUPH leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
AUPH leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, AUPH's 20.2x EV/EBITDA is more attractive than LGND's 356.3x.
| Metric | AUPHAurinia Pharmaceu… | LGNDLigand Pharmaceut… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $2.1B | $4.6B | $2.5B | $4.5B |
| Enterprise ValueMkt cap + debt − cash | $2.1B | $4.5B | $3.3B | $4.7B |
| Trailing P/EPrice ÷ TTM EPS | 7.75x | -1055.91x | -4.29x | -80.50x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.72x | 26.12x | — | 40.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 20.18x | 356.28x | — | 140.62x |
| Price / SalesMarket cap ÷ Revenue | 7.50x | 27.32x | 3.65x | 8.46x |
| Price / BookPrice ÷ Book value/share | 3.83x | 5.12x | — | 22.73x |
| Price / FCFMarket cap ÷ FCF | 15.67x | 58.99x | — | — |
AUPH leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
AUPH leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
AUPH delivers a 49.4% return on equity — every $100 of shareholder capital generates $49 in annual profit, vs $-9 for RARE. LGND carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 2.29x. On the Piotroski fundamental quality scale (0–9), AUPH scores 7/9 vs RARE's 4/9, reflecting strong financial health.
| Metric | AUPHAurinia Pharmaceu… | LGNDLigand Pharmaceut… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +49.4% | +5.1% | -9.1% | -6.1% |
| ROA (TTM)Return on assets | +38.2% | +3.3% | -43.1% | -1.6% |
| ROICReturn on invested capital | +16.6% | -2.3% | -89.4% | +4.8% |
| ROCEReturn on capital employed | +18.9% | -2.7% | -46.4% | +4.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.13x | 0.01x | — | 2.29x |
| Net DebtTotal debt minus cash | -$5M | -$65M | $842M | $230M |
| Cash & Equiv.Liquid assets | $80M | $72M | $434M | $214M |
| Total DebtShort + long-term debt | $75M | $7M | $1.3B | $444M |
| Interest CoverageEBIT ÷ Interest expense | — | 22.69x | -8.37x | 1.11x |
AUPH leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LGND leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LGND five years ago would be worth $17,842 today (with dividends reinvested), compared to $2,359 for RARE. Over the past 12 months, FOLD leads with a +121.9% total return vs RARE's -35.7%. The 3-year compound annual growth rate (CAGR) favors LGND at 43.1% vs RARE's -19.1% — a key indicator of consistent wealth creation.
| Metric | AUPHAurinia Pharmaceu… | LGNDLigand Pharmaceut… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.5% | +22.2% | +6.0% | +1.5% |
| 1-Year ReturnPast 12 months | +94.2% | +118.4% | -35.7% | +121.9% |
| 3-Year ReturnCumulative with dividends | +38.8% | +192.8% | -47.0% | +19.3% |
| 5-Year ReturnCumulative with dividends | +30.7% | +78.4% | -76.4% | +51.1% |
| 10-Year ReturnCumulative with dividends | +487.5% | +96.5% | -60.0% | +121.9% |
| CAGR (3Y)Annualised 3-year return | +11.5% | +43.1% | -19.1% | +6.0% |
LGND leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs RARE's 59.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AUPHAurinia Pharmaceu… | LGNDLigand Pharmaceut… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.86x | 0.99x | 1.42x | 0.63x |
| 52-Week HighHighest price in past year | $16.88 | $247.38 | $42.37 | $14.50 |
| 52-Week LowLowest price in past year | $7.29 | $98.89 | $18.29 | $5.51 |
| % of 52W HighCurrent price vs 52-week peak | +95.0% | +93.9% | +59.0% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 52.6 | 56.4 | 59.6 | 72.2 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 216K | 1.7M | 2.9M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AUPH as "Buy", LGND as "Buy", RARE as "Buy", FOLD as "Buy". Consensus price targets imply 105.9% upside for RARE (target: $52) vs -3.4% for AUPH (target: $16).
| Metric | AUPHAurinia Pharmaceu… | LGNDLigand Pharmaceut… | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $15.50 | $267.75 | $51.50 | $14.50 |
| # AnalystsCovering analysts | 14 | 17 | 33 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +4.6% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AUPH leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). LGND leads in 1 (Total Returns).
Best OverallAurinia Pharmaceuticals Inc. (AUPH)Leads 3 of 6 categories
Loading custom metrics...
AUPH vs LGND vs RARE vs FOLD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AUPH or LGND or RARE or FOLD a better buy right now?
For growth investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger pick with 32. 3% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 7. 7x trailing P/E (19. 7x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AUPH or LGND or RARE or FOLD?
On forward P/E, Aurinia Pharmaceuticals Inc.
is actually cheaper at 19. 7x.
03Which is the better long-term investment — AUPH or LGND or RARE or FOLD?
Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +78.
4%, compared to -76. 4% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: AUPH returned +487. 5% versus RARE's -60. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AUPH or LGND or RARE or FOLD?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 125% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 2% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AUPH or LGND or RARE or FOLD?
By revenue growth (latest reported year), Amicus Therapeutics, Inc.
(FOLD) is pulling ahead at 32. 3% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, AUPH leads at 28. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AUPH or LGND or RARE or FOLD?
Aurinia Pharmaceuticals Inc.
(AUPH) is the more profitable company, earning 101. 5% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus -79. 5% for RARE. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AUPH or LGND or RARE or FOLD more undervalued right now?
On forward earnings alone, Aurinia Pharmaceuticals Inc.
(AUPH) trades at 19. 7x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 20. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 105. 9% to $51. 50.
08Which pays a better dividend — AUPH or LGND or RARE or FOLD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AUPH or LGND or RARE or FOLD better for a retirement portfolio?
For long-horizon retirement investors, Aurinia Pharmaceuticals Inc.
(AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +487. 5% 10Y return). Both have compounded well over 10 years (AUPH: +487. 5%, RARE: -60. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AUPH and LGND and RARE and FOLD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(AUPH: 28.8% · LGND: 122.8%)Net Margin>
%
(AUPH: 101.5% · LGND: 19.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.